A DNA scaffold that carries HIV vaccine proteins into the body sharpens the immune response against the virus.

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Godfrey Dzhivhuho has dedicated his career to understanding HIV and other infectious diseases, inspired by the epidemic he witnessed growing up. Raised in Warrenton-Kimberly, South Africa, the oldest ...

Can HIV cure be achieved in children? Children with HIV face a lifetime of antiretroviral therapy (ART) to suppress HIV replication. While this is one outlook, an HIV cure in children would re-write ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

Children born with HIV and treated early with antiretroviral therapy (ART) continued to show elevated immune markers in adolescence, based on data presented at the International AIDS Society ...

Implementation science data for Apretude (cabotegravir long-acting (CAB LA) for PrEP) demonstrate 95% of participants were happy they switched from oral PrEP to CAB LA Jean van Wyk, MBChB, MFPM, Chief ...